We first determined the effects of CRISPR-Cas9-mediated KO of Menin on MLL1/MLL1-FP targets in AML MOLM13 cells that harbor MLL1-r, FLT3-ITD, and two copies of wild-type TP53. This evidence concerns the gene FLT3 and acute myeloid leukemia.